Monday, June 15, 2026

Exynos 2500 Chip Lands in Galaxy Z Flip 7—Samsung Bets on 3nm Tech

Samsung's Park Yong In updates on Exynos 2600 progress, highlighting the success of Exynos 2500 in Galaxy Z Flip 7 amid challenges.

Apple’s iPad Faces Pressure From Rising Wave of E-Ink Productivity Tablets

The iPad faces challenges from evolving E-ink tablets, which have become strong alternatives in productivity and simplicity.

NEVER-ENDING Threat: Kim Jong Un Fires 4 Times In Two Weeks—The Peninsula Is Under Constant Attack

North Korea launched a suspected ballistic missile into the East Sea on November 7, heightening military readiness in the region.

Tag: cancer

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

2026 Breakthrough in Stomach Cancer: How Proximal Gastrectomy Enhances Quality of Life

Professor Kim Hyung-il's study shows proximal gastrectomy's effectiveness for early-stage stomach cancer, enhancing patient quality of life.

Why Samsung Medical Center is Now Korea’s Top Hospital: A Deep Dive into the 2026 Rankings

Samsung Medical Center ranks as South Korea's top hospital and 26th globally in Newsweek's World's Best Hospitals 2026 list.

Northwell Health Partners with Rokit Healthcare: What This Means for Skin Cancer Treatment in 2026

Northwell Health partners with Rokit Healthcare to advance skin cancer regeneration and wound healing technologies in the U.S. market.

Why Centrum Multivitamins Are Backed by 32 Clinical Studies: A Deep Dive into Their Proven Benefits

Centrum multivitamins stand out for their extensive research backing, showing benefits in cancer risk reduction and cognitive function.

World Cancer Day 2026: How Patient-Centered Care is Transforming Cancer Treatment in Asia

The National Cancer Center joins a global campaign for World Cancer Day, promoting People-Centered Care through dialogue with patients.

GCC2005: The Breakthrough CAR-NK Therapy for T-Cell Lymphoma Unveiled at TCLF 2026

GC Cell presents promising CD5-targeting CAR-NK therapy GCC2005 for T-cell lymphoma, showing significant efficacy and safety at TCLF.

Celltrion’s Remsima SC: The Leading Autoimmune Drug with 68% Market Share in Europe

Celltrion's treatments for autoimmune diseases and cancer maintain strong market positions in Europe, bolstered by stable prescriptions and new products.

Male Breast Cancer Has More Than Doubled in 16 Years—So Why Haven’t Survival Rates Improved?

A study shows male breast cancer cases have doubled in 16 years, but survival rates remain low, highlighting treatment disparities.

Revolutionary mRNA Cancer Treatment Shows 49% Survival Improvement: What You Need to Know

A study shows mRNA-based cancer treatments significantly improve survival rates, marking a breakthrough in precision therapy for melanoma.

2023 Cancer Statistics: Prostate Cancer Surges to Top Spot Among Men in Korea

Prostate cancer is now the most common cancer in South Korean men, reflecting demographic shifts and improved survival rates.

Nesuparib vs. Traditional Treatments: Will This New Dual-Target Cancer Drug Change the Game for Ovarian Cancer?

Onconic Therapeutics advances Nesuparib into Phase 2 trials for ovarian cancer, aiming to validate a novel re-maintenance therapy approach.

NK Cell Cancer Therapies Move Closer to Market as Matica BioLabs Partners With Ingenium

CHA Biotech's Matica BioLabs partners with Ingenium Therapeutics for NK cell therapy production, targeting cancer treatment advancements.

ABL206: First-in-Class Dual Antibody Drug Conjugate Approved for Clinical Trials in the U.S. – What This Means for Cancer Treatment

ABL Bio and Neok Bio received FDA approval for ABL206, a dual-antibody ADC, marking a key milestone in their clinical development efforts.

K-Bio Revolution: How Korean Biopharmaceuticals Are Conquering the Global Market in 2026

South Korea's pharmaceutical industry thrives with innovative drugs like botulinum toxins and cancer treatments, targeting global markets.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.